Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Adverum Biotechnologies, Inc. to Eli Lilly and Company for Adverum shareholders, focusing on the adequacy of the offered compensation and the board's fiduciary duties [1][3]. Group 1: Transaction Details - Adverum shareholders are set to receive $3.56 per share in cash, along with a non-transferrable contingent value right (CVR) that could yield up to an additional $8.91 per CVR upon achieving specific milestones [1]. Group 2: Legal Investigation - The investigation aims to determine if Adverum and its board violated federal securities laws or breached fiduciary duties by not securing the best possible consideration for shareholders, assessing whether Eli Lilly is underpaying, and failing to disclose all material information necessary for shareholders to evaluate the merger [3]. Group 3: Potential Actions - Halper Sadeh LLC may pursue increased compensation for shareholders, additional disclosures, and other forms of relief related to the proposed transaction [4].

Group 1 - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by officers and directors of Gaia, Inc. [1] - Shareholders who acquired Gaia stock on or before December 26, 2017, may seek corporate governance reforms and other benefits [2] - The firm emphasizes the importance of shareholder involvement in improving company policies and enhancing shareholder value [3] Group 2 - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct [4] - The firm operates on a contingent fee basis, meaning no upfront legal fees for shareholders pursuing claims [2]

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Lantheus made false statements and concealed information regarding its revenue outlook and growth potential, particularly related to the sales growth of its product Pylarify [2]. - Allegations include that Lantheus misrepresented its understanding of market pricing and competitive dynamics, leading to an overly optimistic portrayal of its financial prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified period have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating a no-cost participation in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Points - Tronox Holdings plc is facing a class action securities lawsuit due to alleged securities fraud that occurred between February 12, 2025, and July 30, 2025 [1] - The lawsuit claims that Tronox provided misleading statements about its commercial division and failed to accurately forecast demand for its products, leading to a significant decline in sales and a lowered financial outlook [2] - Following the announcement of poor financial results for Q2 2025, Tronox's stock price dropped approximately 38% in one day, from $5.14 to $3.19 per share [2] Company Performance - Tronox's Q2 2025 financial results revealed a significant reduction in TiO2 sales, attributed to a weaker coatings season and increased competition [2] - The company revised its full-year revenue guidance downward and reduced its dividend by 60% due to the sales decline [2] Legal Proceedings - Investors who suffered losses during the specified timeframe have until November 3, 2025, to request to be appointed as lead plaintiff in the class action [3] - Participation in the lawsuit does not require any out-of-pocket costs for class members [3] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr plummeted by 83.2%, from $6.03 on September 12, 2025, to $1.02 on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Case Details - The complaint alleges that aTyr provided positive statements while concealing material adverse facts about Efzofitimod [2] - The EFZO-FIT study's failure to meet its primary endpoint was disclosed during an investor call on September 15, 2025 [2] - aTyr plans to engage with the FDA to determine the next steps after the disappointing study results [2] Next Steps - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [4]

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2]. - It is alleged that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [2]. - The statements made by the defendants regarding LifeMD's business, operations, and prospects are claimed to be materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 27, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - WPP plc is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 27, 2025, and July 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that WPP provided misleadingly positive statements while concealing adverse facts about its media arm's ability to handle macroeconomic challenges, leading to a loss of market share [2]. - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing this to macroeconomic uncertainty and weaker new business, compounded by ongoing restructuring efforts [2]. - Following the trading update, WPP's stock price dropped from $35.82 to $29.34 per share, marking an 18.1% decline in a single day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4].

Core Viewpoint - A class action securities lawsuit has been filed against Fortinet, Inc. for alleged securities fraud affecting investors between November 8, 2024, and August 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Fortinet's management made false statements regarding the refresh cycle of their products, suggesting it would be more profitable than it actually was, as it involved older products that represented a "small percentage" of the company's business [2]. - It is alleged that Fortinet misrepresented the number of FortiGate firewalls eligible for upgrades and that the company had pushed through approximately half of the refresh in just a few months, contrary to claims of a gradual momentum over two years [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 21, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against KBR, Inc. alleging securities fraud that affected investors between May 6, 2025, and June 19, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [2]. - It is alleged that the defendants' statements about KBR's business operations and prospects were materially false and misleading, lacking a reasonable basis during the relevant time [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 18, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].